Influence of Chocolate With Plant Additives on Episodic Memory in Healthy Subjects Experiencing Test Anxiety
NCT ID: NCT03382067
Last Updated: 2018-09-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
128 participants
INTERVENTIONAL
2017-12-04
2018-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A Total of 128 participants, 64 in each group, approx. equal number of male and female. There will be replacement of Drop-Outs until data from 128 participants are completed.
The primary endpoints will be performance in a pictorial memory task and a verbal memory task .
The secondary endpoints will be performance in a working memory test, Saliva cortisol, Visual analog scales assessing, anxiety, confidence, interference, solicitude, and excitement.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Delta9-tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R33 Study
NCT04080427
Effects of Delta-9 Tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R61 Study
NCT03008005
Effects of THC and CBD on Human Episodic Memory Function
NCT02291562
Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects
NCT06884514
Effects of THC on Emotional Memory Retrieval
NCT03471585
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High Epicatechin/ Melissa
Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa ® chocolate + 7.2g caster sugar + 5g Melissa containing 374 mg (-)-Epicatechin/100g chocolate and 2,69% of rosmarinic acid in Melissa leaves
High Epicatechin/ Melissa
Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa chocolate + 7.2g caster sugar + 5g Melissa
Low Epicatechin/ Oat bran
Single consumption of a 55g bar of white chocolate containing: 50g Lindor ® chocolate + 5g oat bran containing \< 0,0009 mg (-)-Epicatechin/100g
Low Epicatechin/ Oat bran
Single consumption of a 55g bar of white chocolate containing: 50g Lindor chocolate + 5g oat bran
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High Epicatechin/ Melissa
Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa chocolate + 7.2g caster sugar + 5g Melissa
Low Epicatechin/ Oat bran
Single consumption of a 55g bar of white chocolate containing: 50g Lindor chocolate + 5g oat bran
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* normotensive (BP between 90/60 mmHg and 140/90 mmHg)
* BMI between 18 and \< 30 kg/m2
* male or female
* aged between 18 and 30 years
* native or fluent German-speaking
* Prüfungsangstfragebogen (PAF) total or subscale interference score T value \> 60
Exclusion Criteria
* gluten intolerance
* lactose intolerance
* acute or chronic psychiatric disorder including drug or alcohol abuse
* women who are pregnant or breast feeding
* any clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease etc., infections)
* known or suspected non-compliance
* smoking (\> 5 cigarettes per day)
* participation in one of our previous studies using the same memory tests in the past 2 years
* participation in a study with investigational drug within the 30 days preceding and during the present study
* long-term medication within last 3 months (oral contraceptives are disregarded)
18 Years
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Prof. Dominique de Quervain, MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dominique de Quervain, MD
Prof. Dominique de Quervain, MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dominique DeQuervain, Prof. MD
Role: PRINCIPAL_INVESTIGATOR
University Basel Divison of Cognitive Neuroscience
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Basel, Division of Cognitive Neuroscience
Basel, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MaRS-Basel
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.